While Edwards expressed disappointment over the court’s ruling, it said that the ruling does not impact any of its businesses because the company discontinued its AAA product line in April 2006. Another co-defendant in this case settled with Edwards in January 2006 under terms including a payment of $37.5 million.

Edwards Lifesciences provides products and technologies used for the treatment of patients suffering from advanced cardiovascular disease.